# Dewpoint Therapeutics

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/dewpoint-therapeutics

- Industry: Pharmaceuticals
- Headquarters: Boston, US
- Website: www.dewpointx.com
- Total disclosed funding: $286M
- Latest round: Series C (Jan 26, 2022)
- Investors on record: 17

## About

Dewpoint Therapeutics, Inc. is focused on developing therapies targeting biomolecular condensates to address complex diseases, including neurodegenerative conditions and various cancers, through innovative small molecule modulators.Dewpoint Therapeutics, Inc. specializes in the development of therapies that target biomolecular condensates, fundamental to cellular organization and function. Founded in 2018, the company is headquartered in Boston, US. The CEO is Ameet Nathwani, with Richard Young as the founder. In September 2025, Dewpoint Therapeutics, Inc. raised an undisclosed amount in Series D funding from unspecified investors. The company has successfully completed four funding rounds, indicating strong investor confidence in their pipeline, and currently boasts a valuation of USD 504.48 mn.Dewpoint Therapeutics specializes in the development of innovative therapies targeting biomolecular condensates, which are crucial for cellular organization and function. Their primary focus lies in crafting small molecule modulators aimed at addressing complex diseases associated with dysregulated condensates, including neurodegenerative conditions like ALS and various cancers such as colorectal, breast, and lung cancers. The company's product offerings aim to rescue cellular function and restore health by leveraging the unique properties of these condensates. Dewpoint collaborates with leading global pharmaceutical partners to enhance their therapeutic pipeline, which spans a range of diseases previously deemed undruggable. Their products are primarily marketed to pharmaceutical companies and research institutions engaged in drug discovery and development, with a focus on the North American and European markets.Dewpoint Therapeutics operates within a partnership-based revenue model, primarily generating funds through strategic alliances and collaborations with pharmaceutical companies. The company has successfully raised USD 345.43  mn across several funding rounds, comprising Series A, B, and C investments, indicating strong investor confidence in their product pipeline. Revenue streams may include milestone payments and royalties from partnerships, particularly as the company advances its lead development candidates, such as DPTX3496, through clinical stages. Clients typically engage in transactions structured around R&D collaborations, where they commit to funding research in exchange for access to therapeutic developments and technology. The company’s anticipated revenues are projected to exceed USD 2 bn from partnerships, excluding royalties.In January 2022, Dewpoint Therapeutics, Inc. raised USD 150 mn in Series C funding to enhance their integrated, multi-component biology platform and support their artificial intelligence-driven data science platform. The company plans to utilize this funding to support multiple pipeline programs through to Investigational New Drug (IND) submission. Dewpoint aims to expand into various geographies, specifically targeting new markets in North America and Europe, as they work towards launching new products focused on biomolecular condensates.

## Funding rounds

- Series C, Jan 26, 2022, $150M — ARCH Venture Partners, General Catalyst Partners, Polaris Partners, Maverick Capital, Mirae Asset Capital, EcoR1 Capital, 3E Bioventures Capital, SB Investment Advisers, Timefolio Capital, Mubadala Capital, Samsara BioCapital, Leaps by Bayer
- Series B, Sep 29, 2020, $77M — ARCH Venture Partners, Polaris Partners, Maverick Capital, Innovation Endeavors, EcoR1 Capital, Samsara BioCapital, Bellco Capital, Leaps by Bayer
- Series A, Jan 30, 2019, $59M — Polaris Partners, Alexandria Venture Investments, Bayer AG, EcoR1 Capital, 6 Dimensions Capital, Samsara BioCapital

## Investors

- Polaris Partners (https://capitalatlas.ai/funds/polaris-partners) — Series A, Series B, Series C
- Alexandria Venture Investments (https://capitalatlas.ai/funds/alexandria-venture-investments) — Series A
- Bayer AG — Series A
- EcoR1 Capital (https://capitalatlas.ai/funds/ecor1-capital) — Series A, Series B, Series C
- 6 Dimensions Capital (https://capitalatlas.ai/funds/6-dimensions-capital) — Series A
- Samsara BioCapital (https://capitalatlas.ai/funds/samsara-biocapital) — Series A, Series B, Series C
- ARCH Venture Partners (https://capitalatlas.ai/funds/arch-venture-partners) — Series B, Series C
- Maverick Capital (https://capitalatlas.ai/funds/maverick-capital) — Series B, Series C
- Innovation Endeavors (https://capitalatlas.ai/funds/innovation-endeavors) — Series B
- Bellco Capital (https://capitalatlas.ai/funds/bellco-capital) — Series B
- Leaps by Bayer (https://capitalatlas.ai/funds/leaps-by-bayer) — Series B, Series C
- General Catalyst Partners (https://capitalatlas.ai/funds/general-catalyst-partners) — Series C
- Mirae Asset Capital (https://capitalatlas.ai/funds/mirae-asset-capital) — Series C
- 3E Bioventures Capital (https://capitalatlas.ai/funds/3e-bioventures-capital) — Series C
- SB Investment Advisers (https://capitalatlas.ai/funds/sb-investment-advisers) — Series C
- Timefolio Capital — Series C
- Mubadala Capital (https://capitalatlas.ai/funds/mubadala-capital) — Series C